Other News

 “SILENTLY LOSING THE BRAIN – The enigma of small vessel disease” Come to Copenhagen for the next Brain Prize Meeting in November 2019. With international keynote speakers, including the 2019 prize winners, the Lundbeck Foundation Brain Prize Meeting aims to bring a broad range of researchers to discuss why small vessel disease has emerged as a major contributor to dementia, migraine and stroke worldwide.

The European Medicines Agency has recommended that the multiple sclerosis medicine Gilenya (fingolimod) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using Gilenya, the medicine must be stopped and the pregnancy will have to be closely monitored. This is because the active substance in Gilenya, fingolimod, can harm the unborn baby and may cause birth defects.

News from other societies

Ahead of discussions on the new Multiannual Financial Framework (EU Budget for 2021-2027) during the European Council Summit on 20-21 June, the BioMed Alliance together with the EU Health Coalition partners published a statement advocating for a more substantial EU research budget.

Early Bird rates for the 29th Alzheimer Europe Conference (#29AEC) closed on 30 June 2019. Alzheimer Europe is delighted to announce that almost 600 delegates have already registered, with many more expected between now and close of online registrations, on 13 October 2019. The number of registrations so far has exceeded all previous years. Alzheimer Europe is excited to see everyone there, for what promises to be a diverse and engaging conference.

In this article, our goal is to provide a glimpse into the excellent collaboration and cooperation our organization has had with the European Federation of Neurorehabilitation Societies (EFNR).

Science|Business is canvassing views on the big research priorities for the next term of the EU, from 2019 to 2024. Here, six policy experts discuss the most pressing items on the EU’s to-do list for health.

Neuronet Scientific Coordination Board meeting brings together project leaders from across the IMI neurodegenerative disease portfolio, encompassing EUR 260 million of funding

The #BrainLifeGoals campaign is an initiative of the European Federation of Neurological Associations that aims to raise awareness of the impact of neurological disorders.

Successful collaboration between the EAN and the International Neuro-urology Society (INUS) at the 7th annual International Neuro-urology Meeting in Zurich. The 7th International Neuro-urology Meeting was held in January 2019 and for the first time, a dedicated Neurosciences workshop was held in collaboration with the EAN. The half-day workshop on Thursday 24 January 2019 began with imaging research and our understanding of the neural control of the lower urinary tract, and included topics such as a review of the neural networks responsible for lower urinary tract control, potential brain imaging biomarkers to evaluate therapeutic interventions for LUT dysfunction and Neuroimaging of functional recovery in SCI. 

Interview with Prof. Claudio Baracchini - President of the ESNCH Prof. Dafin Muresanu interviews President of the ESNCH, Prof. Claudio Baracchini

Migraine is the number one cause of disability affecting people under the age of fifty years  ( the group with the highest contribution to workforce worldwide) making one of the highest negative economic impacts globally(1).  According to the latest analysis from the GBD study, almost 3 billion people had a headache disorder in 2016: 1.89 billion had a diagnosis of tension-type headache, and 1.04 billion had a diagnosis of migraine(2). Migraine was responsible for 45.12 million years of life lived with disability (YLD), with a peak in prevalence in women between 15 and 49 years(3). One in seven suffer from this disabling, least respected, worst managed, least recognised complex brain disorder worldwide(5).

Governmental Expert Group on Dementia holds second meeting The European Group of Governmental Experts on Dementia held its second meeting on 17 and 18 June 2019 in Amsterdam, The Netherlands. 20 European countries were represented at the meeting, in addition to representatives from the 2nd European Joint Action on Dementia (Act on Dementia/DEM2), the World Health Organization (WHO) and Alzheimer Europe.

A Memorandum of Understanding (MoU) with the European Society of Neurosonology and Cerebral Hemodynamics (ESNCH) was signed in June 2019. The ESNCH is the most successful neurosonology group worldwide bringing together the world’s experts, thus representing an excellent platform for young researchers to present their work, gain experience and start a scientific collaboration.

Task Force Regulatory Affairs and Medical Devices Workshop on Medical Device Registries: The BioMed Alliance organised a joint workshop on Medical Device Registries with the European Society of Cardiology (ESC) and the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) on 17 June. The programme included speakers from the European Commission, member societies, a notified body, industry, the European Medicines Agency and experts who manage successful registries across Europe.